The rationale for using PD-L1 positive CTCs (PD-L1+CTCs) as a potential biomarker include: (1) PD-L1 expressed on CTCs plays an important role in tumor progression and metastasis, as well as resistance of anti-PD-(L)1 immunotherapy [71,72]. Here, CD274 is linked to neoplasm.